SCHEMBL863333

SCHEMBL863333

Fc1ccc(F)c(-c2nnc3ccc(-c4ccc5[nH]ccc5c4)nn23)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUSB P08236 1/20 0.43
AHR P35869 1/20 0.43
DYRK3 O43781 3/20 0.39
CCNT1 O60563 3/20 0.39
CDK9 P50750 3/20 0.39
CDK5 Q00535 3/20 0.39
DYRK1A Q13627 3/20 0.39
CDK5R1 Q15078 3/20 0.39
DYRK2 Q92630 3/20 0.39
DYRK1B Q9Y463 3/20 0.39
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
MET P08581 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864043 0.85 MET (0.43) GUSBAHRDYRK3CCNT1CDK9
SCHEMBL863714 0.80 DYRK3 (0.46) GUSBDYRK3CCNT1CDK9CDK5
SCHEMBL863630 0.79 NPC1 (0.52) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL16174464 0.79 MAOB (0.43) L3MBTL1GABRA1GABRG2GABRB3GABRA5
SCHEMBL863990 0.76 MET (0.42) L3MBTL1GABRA1GABRG2GABRB3GABRA5
SCHEMBL16009418 0.68 DYRK3 (0.77) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL10094662 0.68 AHR (0.61) GUSBAHRPIK3CDPIK3CAMTOR
SCHEMBL7091087 0.67 AHR (0.65) GUSBAHRDYRK1ADYRK2DYRK1B
SCHEMBL856313 0.65 AHR (0.70) GUSBAHRPIK3CDPIK3CAMTOR
SCHEMBL228554 0.64 AHR (1.00) GUSBAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed
EP-2406264-A2 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS The Regents of The University of California (US) 2012-01-18 EP disclosed
WO-2010104843-A2 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS CHRNA7, CHRNA5, CHRNA1 GUSB 3021/4885AHR 795/4885DYRK3 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.